Globaldata

DATA · Main Market · Industrial Goods and Services · mcap £390m · 59.3p

GlobalData sells subscription data, analytics and research to companies in sectors such as healthcare, technology and finance. Most revenue is recurring and comes from annual contracts.

Recent signals

Negative 14 Sep 2026

Guidance cut: FY26 revenue at lower end and EBITDA below expectations; medium-term margin recovery slowed

Margin target of 40% now more measured; share price fell to about 59p. 14 Sep 2026 9 Jul 2026

Mixed 14 Sep 2026

Repeated tenders and buybacks while net bank debt rose to £133m

Capital returns funded partly by debt, with over £49m returned in FY26. 14 Sep 2026

Negative 17 Aug 2026

CEO Mike Danson sold 20m shares in Sept 2025 and 20.1m in Aug 2026

Large insider sales, though Danson remains the major holder and sold partly via tender offer. 17 Aug 2026 12 Sep 2025

Positive 28 Oct 2025

Liontrust and other holders increased stakes above 5%

Several institutions built holdings during falling share price. 28 Oct 2025 26 Aug 2025

Negative 11 Jun 2025

Takeover interest from KKR and ICG ended without offers in 2025

Both bidders walked away; share price has since fallen sharply. 11 Jun 2025 28 May 2025

Capital actions

2026-07-10 tender offer · £30m – Tender offer for 35.3m shares at 85p, completed August 2026 10 Jul 2026
2026-06-23 buyback programme · £5m – Buyback programme completed, 6.7m shares repurchased at average 59.4p 23 Jun 2026
2025-08-05 tender offer · £60.0m – Tender offer for 40m shares at £1.50 per share, approved by shareholders and completed September 2025 5 Aug 2025
2025-02-06 buyback programme · £50m – Share buyback programme launched, to run until 31 August 2025; suspended May 2025 on entering offer period 6 Feb 2025
2024-12-19 debt refinancing · £340m – New debt facilities maturing December 2027 to fund M&A 19 Dec 2024
2024-06-28 disposal · £434m – Inflexion acquired 40% of Healthcare division, valuing it at £1,115m; net cash proceeds 5 Jun 2024

Risks & opportunities

Opportunities

Reducing churn and lifting volume renewal rates would improve organic growth since 2026-09 14 Sep 2026
AI-first transformation to drive efficiencies from late H2 FY26 into FY27 since 2026-09 14 Sep 2026
Healthcare division M&A and Non-Healthcare revenue synergies from recent acquisitions since 2026-03 2 Mar 2026

Risks

Underlying revenue growth more muted than expected; FY26 EBITDA below market expectations since 2025-08 14 Sep 2026
Elongated sales cycles and challenging macroeconomic backdrop since 2025-08 5 Aug 2025
Currency headwinds, with c.50% of revenue in USD since 2025-08 14 Sep 2026
Net bank debt rose to £133.0m from £16.8m since 2025-08 14 Sep 2026

As the company itself describes them.

Coming up

FY26 FY26 results; Adjusted EBITDA guided below market expectations

From the company's own announcements · not investment advice

Company filings. Not investment advice.